Online inquiry

IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8436MR)

This product GTTS-WQ8436MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets TLR3 Agonist. The antibody can be applied in Cervical dysplasia vaccine research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Mycobacterium tuberculosis variant bovis; Alphapapillomavirus 9
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8436MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2696MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ4450MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-734016
GTTS-WQ11408MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI-575
GTTS-WQ11539MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MGA031
GTTS-WQ3804MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BB-10901
GTTS-WQ9237MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMMU-107
GTTS-WQ8050MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ4360MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-188667
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW